Document is current
Any future updates will be listed below
-
Authors
Rathgeber, Anja C.
Fernandes, Stacey M.
Nagler, Adi
Li, Shuqiang
Dorfman, David M.
Bullinger, Lars
Davids, Matthew S.
Brown, Jennifer R.
Livak, Kenneth J.
Ludwig, Leif S.
Wu, Catherine J.
Penter, Livius https://orcid.org/0000-0002-9060-0207
-
Funding
Funding for this research was provided by:
Leukemia and Lymphoma Society (5648-24)
National Cancer Institute (R50CA251956)
National Cancer Institute (R01 CA266298)
National Cancer Institute (P01 CA206978)
Deutsche Forschungsgemeinschaft (LU 2336/10-1)
CLL Global Research Fund
Parker Institute for Cancer Immunotherapy
American Society of Hematology
Deutsche Krebshilfe
DKMS John Hansen Research Grant
Else Kröner-Fresenius-Stiftung (2023_EKEA.102)
Brigitte und Dr. Konstanze Wegener-Stiftung (A 2024 II (7))
BIH Charité Digital Clinician Scientist Program
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 4 December 2025
Accepted: 3 April 2026
First Online: 15 April 2026
Declarations
:
: Ethical approval was obtained from the Dana-Farber Cancer Institute Institutional Review Board under protocol 99–224, and all patients provided written informed consent prior to sample and data collection. The experimental methods of this study comply with the Helsinki Declaration.
: All participants signed written informed consent, including for publication of sequencing data, prior to any sample collection.
: The authors declare no competing interests.
